Hiler and Levitt Write on Impact of Amgen v. Sanofi

Taft Intellectual Property attorneys Ryan Hiler and Andrew Levitt wrote the article “Amgen v. Sanofi: Seven Months In, Has Anything About Patent Enablement Changed?” for IPWatchdog on Jan. 9. The article discusses the impact of Amgen v. Sanofi in the seven months since the Supreme Court decision. Read the article here.

Hiler is a partner in Taft’s Intellectual Property group. He represents clients in all aspects of intellectual property law and focuses his practice on patent matters and technology transactions. He has significant experience managing global patent portfolios for clients. Hiler also frequently negotiates and structures strategic intellectual property transactions and drafts contracts. He also acts as outside general intellectual property counsel to numerous companies and provides efficient solutions for his clients that safeguard their assets.

Levitt is an associate in Taft’s Intellectual Property group. His practice includes patent prosecution, invalidity, and non-infringement opinions; prior art, clearance, and freedom-to-operate searches; as well as patent landscape studies, with a focus on biological sciences, pharmaceutical sciences, biochemistry, and biomedical instruments and methods. He also has experience handling clearance matters, as well as intellectual property transactions and licensing.

In This Article

You May Also Like